Picture of American Cryostem logo

CRYO American Cryostem Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro Cap

Momentum

Relative Strength (%)
1m-2.64%
3m+9178.01%
6m-92.26%
1yr-99.93%
Volume Change (%)
10d/3mn/a
Price vs... (%)
52w High-99.94%
50d MA-92.92%
200d MA-99.91%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capitaln/a
Return on Equityn/a
Operating Margin1608.72%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
30th Sep 202230th Sep 2023
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2022 / 2023

Blurred out image of American Cryostem EPS forecast chart

Profile Summary

American CryoStem Corporation is a biotechnology company. The Company has developed adipose tissue-derived technologies (Adult Stem Cells) for the fields of regenerative and personalized medicine. Its technologies are the basis for the chemistry, manufacturing, and controls (cGMP Manufacturing) of its ATCell autologous cellular therapy product for use in clinical investigations for biologic license applications with the United States Food and Drug Administration (FDA). The Company has developed and refined its pipeline around its cellular product, ATCell, for clinical therapeutic use. The Company’s ATCELL cell lines are cultured in its patented ACSelerate cell culture media. Its CELLECT service is the required platform for the collection and transportation of live adipose tissue samples to its processing facility. Its ACSelerate cell culture media products are manufactured using patented cell culture media for growing human stromal cells. The Company also includes ATGRAFT services.

Directors

Last Annual
September 30th, 2021
Last Interim
June 30th, 2022
Incorporated
March 13th, 2009
Public Since
October 2nd, 2010
No. of Shareholders
473
No. of Employees
6
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
us flag iconPink Sheets on Nasdaq
Shares in Issue
44,279,279

CRYO Share Price Performance

Upcoming Events for CRYO

Similar to CRYO

Picture of Actavia Life Sciences logo

Actavia Life Sciences

us flag iconPink Sheets on Nasdaq

Picture of Acura Pharmaceuticals logo

Acura Pharmaceuticals

us flag iconPink Sheets on Nasdaq

Picture of Adhera Therapeutics logo

Adhera Therapeutics

us flag iconPink Sheets on Nasdaq

Picture of Ramoil Management logo

Ramoil Management

us flag iconPink Sheets on Nasdaq

Picture of Adynxx logo

Adynxx

us flag iconPink Sheets on Nasdaq

FAQ